Changes in the Immunological Profile of Peripheral Blood Leukocytes in Multiple Sclerosis (MS) Patients Treated with lnterferon-β-1a;Veränderungen des immunologischen Profils von Leukozyten im peripheren Blut von Multiple-Sklerose-(MS-)Patienten, behandelt mit lnterferon-β-1a

LaboratoriumsMedizin

Volumn 25, Issue 5-6, 2001, Pages 157-160

  Zaborski, J ^a   Czlonkowska, Anna ^a   Mirowska, Dagmara ^b   Paź, Aleksandra ^b   Korlak, Janina ^b   Czlonkowski, A ^b   Koronkiewicz, Miroslawa ^c   Skiersk, J ^c  

^a INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c NATIONAL MEDICINES INSTITUTE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; BETA1A INTERFERON; CD14 ANTIGEN; CD16 ANTIGEN; CD19 ANTIGEN; CD3 ANTIGEN; CD38 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; CD86 ANTIGEN; INTERLEUKIN 2 RECEPTOR; MYELIN;

ADULT; ARTICLE; B LYMPHOCYTE; CELL POPULATION; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE COURSE; FEMALE; HUMAN; IMMUNOGLOBULIN PRODUCTION; IMMUNOREGULATION; MALE; MONOCYTE; MULTIPLE SCLEROSIS; PATHOPHYSIOLOGY; TH2 CELL;

EID: 0034952406     PISSN: 03423026     EISSN: 14390477     Source Type: Journal    
DOI: 10.1515/labm.2001.25.5-6.157     Document Type: Article

References (13)

1. Bernard, CCA., Ichikawa, M., Johns, TO., Menon, K., Slavin, A. Autoantigens in experimental autoimnnune encephalomyelitis and multiple sclerosis. In: Abramsky O, Ovadia H, editors. Frontiers in multiple sclerosis Clinical research and therapy. London: Martin Dunitz, 1997: 61–70.
2. Patti, F., L'Episcopo, MR., Cataldi, ML., Reggio, A. Natural interferon-β treatment of relapsing-remitting and secondary-progressive multiple sclerosis patients A two-year study. Acta Neurol Scand 1999;100:283-9.
3. Arnason, BGW., Dayal, A., Qu, ZX., Jensen, MA., Genζ, K., Reder, AT. Mechanism of action of interferon-β in multiple sclerosis. Springer Semin Immunopathol 1996;18:125-48.
4. Mancardi, G., Hart, BA., Capello, E., Brok, HPM., Ben-Nun, A., Roccatagliata, L., Giunti, D., Gazolla, P., Dono, M., de Kerlero, Rosbo N., Colombo, M., Uccelli, A. Restricted immune responses lead to CNS demyelination and axonal damage. J Neuroimmunol 2000; 107: 178-83.
5. Hartung, HP. Pathogenesis of multiple sclerosis. In: Abramsky O, Ovadia H, editors. Frontiers in multiple sclerosis Clinical research and therapy. London: Martin Dunitz, 1997: 45–59.
6. Sellebjerg, F., Jensen, J., Ryder, LP. Costimulatory CD80 (B7-1) and CD86 (B7-2) on cerbrospinal fluid cells in multiple sclerosis. J Neuroimmunol 1998;84:179-87.
7. Jacobs, LD., Beck, RW., Simon, JH., Kinkel, RP., Brownscheidle, CM., Murray, TJ., Simonian, NA., Slasor, PJ., Sandrock, AW. CHAMPS Study Group, Intramuscular interferon-β-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2000;343:898–904.
8. Rudick, RA., Ransohoff, RM., Lee, JC., Peppier, R., Yu, M., Mathisen, PM., Tuohy, VK. In vivo effects if interferon-β-1a on immunosuppressive cytokines in multiple sclerosis. Neurology, 1998;50:1294-300.
9. TM): implications for modern MS trials and therapeutics. J Neuroimmunol 2000; 107: 167-73.
10. Ristori, G., Montesperelli, Ch., Gasperini, C., Battistini, L., Borsellino, G., Buttinelli, C., Cannoni, S., Pema, A., Pozzilli, C., Salvetti, M. T cell response to myelin basic protein before and after treatment with interferon beta in multiple sclerosis. J Neuroimmunol 1999;99:91-6.
11. Poser, C., Paty, DW., Scheinberg, L., McDonald, WI., Davis, FA., Ebers, GC., Johnson, KP., Sibley, WA., Silberberg, DH., Toutelotte, WW. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-31.
12. Arnason, BGW. Interferon beta in the treatment of multiple sclerosis. In; Abramsky O, Ovadia H, editors. Frontiers in multiple sclerosis Clinical research and therapy. London: Martin Dunitz, 1997:223-8.
13. Reder, AT. Clinical Pharmacology of interferon-β-1a and its potential role in multiple sclerosis. Clin Immunother 1996;5 (Suppl. 1):31–40.